Abiopharma

New Form SCHEDULE 13G - Meta Platforms, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000840 <b>Size:</b> 7 KB

New Form SCHEDULE 13G - NEOGENOMICS INC <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000842 <b>Size:</b> 7 KB

New Form SCHEDULE 13G - Moelis & Co <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000848 <b>Size:</b> 7 KB

New Form SCHEDULE 13G - NMI Holdings, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000846 <b>Size:</b> 7 KB

New Form SCHEDULE 13G - METTLER TOLEDO INTERNATIONAL INC/ <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000849 <b>Size:</b> 7 KB

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-195273 <b>Size:</b> 239 KB

New Form SCHEDULE 13G - MARRIOTT INTERNATIONAL INC /MD/ <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000850 <b>Size:</b> 7 KB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001918704-26-011518 <b>Size:</b> 846 KB

New Form SCHEDULE 13G - MAXIMUS, INC. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000847 <b>Size:</b> 7 KB

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001839882-26-021999 <b>Size:</b> 377 KB

New Form SCHEDULE 13G - MKS INC <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000852 <b>Size:</b> 7 KB

New Form SCHEDULE 13G - MFA FINANCIAL, INC. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0002100119-26-000851 <b>Size:</b> 7 KB

Approval was received from the Supervisor of Banks for the early redemption of subordinated notes (Series 10).

(30% Negative) MARCUS CORP (MCS) Reports Q2 2026 Financial Results

(75% Positive) CADRENAL THERAPEUTICS, INC. (CVKD) Provides Update on trial for heparin-induced thrombocytopenia (HIT)